(RCKT) Rocket Pharmaceuticals - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 300m USD | Total Return: 16.2% in 12m
Avg Turnover: 7.18M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Interest Coverage Ratio -43.3 is critical
Altman Z'' -12.48 < 1.0 - financial distress zone
Extended 1w Choppy
Tailwinds
No distinct edge detected
Rocket Pharmaceuticals (RCKT) is a late-stage biotechnology company specializing in the development of gene therapies for rare and life-threatening diseases. The company’s pipeline utilizes two distinct platforms: in vivo adeno-associated viral (AAV) vectors for cardiac conditions like Danon Disease and ex vivo lentiviral (LV) vectors for hematologic disorders such as Fanconi Anemia and Leukocyte Adhesion Deficiency-I.
The business model relies on high-intensity research and development supported by strategic licensing agreements with academic and medical institutions to secure intellectual property. In the biotechnology sector, late-stage firms often face significant capital requirements and regulatory scrutiny as they transition from clinical trials toward potential commercialization.
To better understand the companys long-term valuation and pipeline potential, consider reviewing the comprehensive data available on ValueRay. Founded in 1999 and headquartered in New Jersey, Rocket Pharmaceuticals currently manages multiple programs ranging from preclinical stages to Phase 2 clinical trials.
- FDA approval decisions for LAD-I and Fanconi Anemia gene therapy programs
- Clinical trial data readouts for Danon Disease Phase 2 pivotal study
- High research and development expenses drive significant quarterly cash burn rates
- Strategic licensing agreements and partnerships impact long-term intellectual property valuation
- Regulatory pathway clarity for AAV cardiac programs influences investor confidence levels
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.63 > 0.02 and ΔFCF/TA -17.80 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.63 > 3% & CFO -179.6m > Net Income -209.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.1m) vs 12m ago 1.85% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.95%; Δ -1.95% > 0%) |
| Interest Coverage Ratio: -43.29 > 6 (EBIT TTM -204.7m / Interest Expense TTM 4.73m) |
| A: 0.44 (Total Current Assets 149.8m - Total Current Liabilities 24.5m) / Total Assets 285.4m |
| B: -5.22 (Retained Earnings -1.49b / Total Assets 285.4m) |
| C: -0.54 (EBIT TTM -204.7m / Avg Total Assets 378.2m) |
| D: 5.03 (Book Value of Equity 238.0m / Total Liabilities 47.4m) |
| Altman-Z'' = -12.48 = D |
As of June 18, 2026, the stock is trading at USD 3.16 with a total of 4,535,817 shares traded.
Over the past week, the price has changed by +21.54%,
over one month by +2.93%,
over three months by -31.75% and
over the past year by +16.18%.
Rocket Pharmaceuticals has received a consensus analysts rating of 4.61. Therefore, it is recommended to buy RCKT.
- StrongBuy: 12
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 9.4 | 197.2% |
P/B = 1.2156
Revenue TTM = 0.0 USD
EBIT TTM = -204.7m USD
EBITDA TTM = -194.5m USD
Long Term Debt = 21.8m USD (estimated: total debt 24.8m - short term 2.92m)
Short Term Debt = 2.92m USD (from shortTermDebt, last quarter)
Debt = 24.8m USD (from shortLongTermDebtTotal, last quarter) (leases 24.8m already included)
Net Debt = -119.6m USD (calculated: Debt 24.8m - CCE 144.4m)
Enterprise Value = 180.7m USD (300.3m + Debt 24.8m - CCE 144.4m)
Interest Coverage Ratio = -43.29 (Ebit TTM -204.7m / Interest Expense TTM 4.73m)
EV/FCF = -1.00x (Enterprise Value 180.7m / FCF TTM -179.8m)
FCF Yield = -99.52% (FCF TTM -179.8m / Enterprise Value 180.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 11.0m) / Revenue TTM)
Tobins Q-Ratio = 0.63 (Enterprise Value 180.7m / Total Assets 285.4m)
Interest Expense / Debt = 19.09% (Interest Expense 4.73m / Debt 24.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -161.7m (EBIT -204.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.12 (Total Current Assets 149.8m / Total Current Liabilities 24.5m)
Debt / Equity = 0.10 (Debt 24.8m / totalStockholderEquity, last quarter 238.0m)
Debt / EBITDA = 0.62 (negative EBITDA) (Net Debt -119.6m / EBITDA -194.5m)
Debt / FCF = 0.67 (negative FCF - burning cash) (Net Debt -119.6m / FCF TTM -179.8m)
Total Stockholder Equity = 295.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.36% (Net Income -209.4m / Total Assets 285.4m)
RoE = -70.79% (Net Income TTM -209.4m / Total Stockholder Equity 295.8m)
RoCE = -64.43% (EBIT -204.7m / Capital Employed (Equity 295.8m + L.T.Debt 21.8m))
RoIC = -61.27% (negative operating profit) (NOPAT -161.7m / Invested Capital 263.9m)
WACC = 11.18% (E(300.3m)/V(325.0m) * Re(10.86%) + D(24.8m)/V(325.0m) * Rd(19.09%) * (1-Tc(0.21)))
Discount Rate = 10.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.57 | Cagr: 13.64%
[DCF] Fair Price = unknown (Cash Flow -179.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.35 | Chg30d=N/A | Revisions=+14% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.43 | Chg30d=N/A | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.82 | Chg30d=+40.17% | Revisions=+14% | GrowthEPS=+58.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.13 | Chg30d=+15.25% | Revisions=-14% | GrowthEPS=-38.0% | GrowthRev=+15.3%
[Analyst] Revisions Ratio: +14%